Solid Tumors clinical trials
Showing 401–450 of 1,133 active trials. Describe your situation to see which ones look like a fit.
- A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
- Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies
- A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
- A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)
- Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
- A Study of DS5361b in Participants With Advanced Solid Tumors
- A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
- A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
- Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
- A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors
- A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
- Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
- A Study of BGC515 Capsules in Subjects With Advanced Solid Tumors
- Stereotactic Ablative Radiotherapy (SABR) for the Treatment of Patients With Metastatic Cancer, ID-COMET Trial
- A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
- Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
- A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer
- Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)
- Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.
- JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
- A Study to Test Different Doses of BI 765049 in People With Advanced Cancer of the Colon, Rectum, Stomach, or Pancreas
- A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
- Scalp Cooling for Chemotherapy-Induced Alopecia in Patients of Color
- A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
- Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment
- Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
- A First in Human Study of PLT012 in Participants With Solid Tumor Cancers
- ARC101 in Advanced Solid Tumors
- BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
- Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)
- FIH Study to Evaluate Safety, Tolerability, PK, PD & Preliminary Efficacy of AT03-65 With Advanced Solid Tumors
- Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss
- A Study of PHN-012 in Patients With Advanced Solid Tumors
- Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
- Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
- A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.
- Smoking Cessation CM for Veterans With or at Risk for Cancer
- ProofPrincip IntraTu TCells SinglDoseImmunCheckpoinInhib Gastro-Esophage Adenocarcinoma w/ARID1a Mu
- Personalized Radiotherapy for Individualized Treatment Strategies and Monitoring (PRISM)
- Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
- A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
- A Study of ADRX-0405 in Subjects With Select Advanced Solid Tumors
- R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors
- Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
- TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
- Studying TAK-243 in Patients With Advanced Cancer
- A Study of PYX-201 in Advanced Solid Tumors
- A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy
- A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
Guides for people searching for a trial
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.